Chandigarh Herald

DelveInsight’s, “Chronic Lymphocytic Leukemia Pipeline Insight 2023” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in the Chronic Lymphocytic Leukemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Chronic Lymphocytic Leukemia Pipeline Report

 

• DelveInsight’s Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment.

 

• The leading Chronic Lymphocytic Leukemia Companies include Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others

 

• Promising Chronic Lymphocytic Leukemia Pipeline Therapies include Acalabrutinib, Venetoclax, ABT-263, Bendamustine, Rituximab, Bendamustine, Obinutuzumab, and others.

 

• The Chronic Lymphocytic Leukemia Companies and academics are working to assess challenges and seek opportunities that could influence Chronic Lymphocytic Leukemia (CLL) R&D. The Chronic Lymphocytic Leukemia pipeline therapies under development are focused on novel approaches to treat/improve Chronic Lymphocytic Leukemia.

 

To explore more information on the latest breakthroughs in the Chronic Lymphocytic Leukemia Pipeline treatment landscape of the report, click here @ Chronic Lymphocytic Leukemia Pipeline Outlook

 

Chronic Lymphocytic Leukemia Overview

Chronic Lymphocytic Leukemia (CLL) (also called CLL) is a cancer of the blood and bone marrow that usually gets worse slowly. CLL is one of the most common types of leukemia in adults. It often occurs during or after middle age; it rarely occurs in children. In the beginning, CLL does not cause any signs or symptoms and may be found during a routine blood test.

 

Recent Developmental Activities of Chronic Lymphocytic Leukemia Treatment Landscape

 

• The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ® (umbralisib), the Company’s once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with Chronic Lymphocytic Leukemia (CLL) (CLL) and small lymphocytic lymphoma (SLL). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2022.

 

• Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of Chronic Lymphocytic Leukemia (CLL). 

 

• Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL.

 

For further information, refer to the detailed Chronic Lymphocytic Leukemia Unmet Needs, Chronic Lymphocytic Leukemia Market Drivers, and Chronic Lymphocytic Leukemia Market Barriers, click here for Chronic Lymphocytic Leukemia Ongoing Clinical Trial Analysis

 

Chronic Lymphocytic Leukemia Emerging Drugs Profile

 

• Ublituximab: TG Therapeutics

Ublituximab (TG-1101) is an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell. The U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with UKONIQ® (umbralisib), the Company’s once-daily, oral, inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with Chronic Lymphocytic Leukemia (CLL) (CLL) and small lymphocytic lymphoma (SLL). The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of March 25, 2022.

 

• LOXO305: Loxo Oncology

Pirtobrutinib is an investigational, oral, highly-selective non-covalent Bruton’s tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of Chronic Lymphocytic Leukemia (CLL).

 

• Cirmtuzumab: Oncternal Therapeutics

Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells, but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL.

 

• Olaptesed pegol: NOXXON Pharma

NOX-A12 (olaptesed pegol) is currently under Phase II stage of development as a combination therapy in multiple oncology indications. NOX-A12 targets CXCL12 (C-X-C Chemokine Ligand 12), a key chemokine (signaling) protein. NOX-A12 is designed to fight solid tumors by modulating the tumor microenvironment in two distinct ways: Break tumor protection enabling anti-cancer immune cells, such as killer T-cells, to enter the tumor with the aim of unleashing the full potential of immuno-oncology approaches, such as immune checkpoint inhibitors and Block tumor repair through preventing the attraction of ‘repair cells’ to the tumors obstructing tumor re-growth following radiotherapy.

 

 Chronic Lymphocytic Leukemia Pipeline Therapeutics Assessment

There are approx. 60+ key companies which are developing the therapies for Chronic Lymphocytic Leukemia (CLL). The companies which have their Chronic Lymphocytic Leukemia (CLL) drug candidates in the most advanced stage, i.e. Preregistration include TG Therapeutics.

 

Chronic Lymphocytic Leukemia Pipeline: Phases

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Request a sample and discover the recent advances in Chronic Lymphocytic Leukemia Ongoing Clinical Trial Analysis and Medications, click here @ Chronic Lymphocytic Leukemia Treatment Landscape

 

Scope of the Chronic Lymphocytic Leukemia Pipeline Report

 

• Coverage- Global

 

• Companies- Octapharma, Celgene, Loxo Oncology, Janssen Research & Development, LLC, TG therapeutics, AFA Insurance, MorphoSys AG, Bristol Myers Squibb, IO Biotech, Astex Pharmaceuticals, Novartis, Oncternal Therapeutics, Cellectar Biosciences, Inc., Zhejiang DTRM Biopharma, Incyte Corporation, Millennium Pharmaceuticals, Inc., NOXXON Pharma, Merck Sharp & Dohme Corp, Genentech, Inc., Rhizen Pharmaceuticals, Gilead Sciences/Ono Pharmaceutical, BioInvent International AB, Chongqing Precision Biotech Co., Ltd, Mustang Bio,  Genmab, Genor Biopharma Co., Ltd., Iovance Biotherapeutics, Juno therapeutics, Lava Therapeutics, Miltenyi Biomedicine GmbH, Ascentage Pharma, Aprea Therapeutics, BeiGene, Acerta Pharma BV, and others.

  

• Pipeline Therapies- Acalabrutinib, Venetoclax, ABT-263, Bendamustine, Rituximab, Bendamustine, Obinutuzumab, and others

 

• Chronic Lymphocytic Leukemia Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

  

Dive deep into rich insights for drugs for Chronic Lymphocytic Leukemia Market Drivers and Chronic Lymphocytic Leukemia Market Barriers, click here @ Chronic Lymphocytic Leukemia Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Chronic Lymphocytic Leukemia (CLL): Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Ublituximab: TG Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Cirmtuzumab: Oncternal Therapeutics
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. NX-2127: Nurix
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Chronic Lymphocytic Leukemia (CLL) Key Companies
17. Chronic Lymphocytic Leukemia (CLL) Key Products
18. Chronic Lymphocytic Leukemia (CLL)- Unmet Needs
19. Chronic Lymphocytic Leukemia (CLL)- Market Drivers and Barriers
20. Chronic Lymphocytic Leukemia (CLL)- Future Perspectives and Conclusion
21. Chronic Lymphocytic Leukemia (CLL) Analyst Views
22. Chronic Lymphocytic Leukemia (CLL) Key Companies
23. Appendix

 

Got Queries? Find out the related information on Chronic Lymphocytic Leukemia Mergers and acquisitions, Chronic Lymphocytic Leukemia Licensing Activities @ Chronic Lymphocytic Leukemia Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/